{
    "id": "ded42d67-ec6d-4eb9-b05a-795e3a131b64",
    "indications": {
        "text": "rexulti indicated : adjunctive treatment antidepressants major depressive disorder ( mdd ) adults treatment schizophrenia adults pediatric patients ages 13 years older treatment agitation associated dementia due alzheimer 's disease limitations : rexulti indicated needed ( `` prn `` ) treatment agitation associated dementia due alzheimer 's disease [ ( 14.3 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer rexulti orally daily without food . ( 2 , 12.3 ) indication starting recommended target maximum mdd adults ( 2.2 ) 0.5 mg/day 1 mg/day 2 mg/day 3 mg/day schizophrenia adults ( 2.3 ) 1 mg/day 2 4 mg/day 4 mg/day schizophrenia pediatric ( 13 - 17 years ) ( 2.3 ) 0.5 mg/day 2 4 mg/day 4 mg/day agitation associated dementia due alzheimer 's disease ( 2.4 ) 0.5 mg/day 2 mg/day 3 mg/day moderate severe hepatic impairment : maximum recommended 2 mg daily patients mdd agitation associated dementia due alzheimer 's disease 3 mg daily patients schizophrenia . ( 2.5 ) crcl < 60 ml/minute : maximum recommended 2 mg daily patients mdd agitation associated dementia due alzheimer 's disease 3 mg daily patients schizophrenia . ( 2.6 ) full prescribing information modifications cyp2d6 poor metabolizers concomitant cyp inhibitors inducers . ( 2.7 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "adverseReactions": "rexulti contraindicated patients known hypersensitivity brexpiprazole components . included rash , facial swelling , urticaria , anaphylaxis .",
    "ingredients": [
        {
            "name": "brexpiprazole",
            "code": "2J3YBM1K8C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134716"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        }
    ],
    "organization": "Otsuka America Pharmaceutical, Inc.",
    "name": "Rexulti",
    "effectiveTime": "20250514",
    "indications_original": "REXULTI is indicated for:\n                  \n                     Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults\n                     Treatment of schizophrenia in adults and pediatric patients ages 13 years and older\n                     Treatment of agitation associated with dementia due to Alzheimer's disease \t\t\t\t\t\t\t\n                  \n                  \n                     Limitations of Use:\n                  \n                  REXULTI is not indicated as an as needed (\"prn\") treatment for agitation associated with dementia due to Alzheimer's disease [see \n                        Clinical Studies (14.3)].",
    "contraindications_original": "Administer REXULTI orally once daily with or without food. ( 2 , 12.3 ) Indication Starting Dosage Recommended Target Dosage Maximum Dosage MDD Adults ( 2.2 ) 0.5 mg/day or 1 mg/day 2 mg/day 3 mg/day Schizophrenia Adults ( 2.3 ) 1 mg/day 2 to 4 mg/day 4 mg/day Schizophrenia Pediatric (13 - 17 years) ( 2.3 ) 0.5 mg/day 2 to 4 mg/day 4 mg/day Agitation associated with dementia due to Alzheimer's disease ( 2.4 ) 0.5 mg/day 2 mg/day 3 mg/day Moderate to Severe Hepatic Impairment: Maximum recommended dosage is 2 mg once daily for patients with MDD or agitation associated with dementia due to Alzheimer's disease and 3 mg once daily for patients with schizophrenia. ( 2.5 ) CrCl<60 mL/minute: Maximum recommended dosage is 2 mg once daily for patients with MDD or agitation associated with dementia due to Alzheimer's disease and 3 mg once daily for patients with schizophrenia. ( 2.6 ) See Full Prescribing Information for dosage modifications for CYP2D6 poor metabolizers and for concomitant use with CYP inhibitors or inducers. ( 2.7 )",
    "adverseReactions_original": "REXULTI is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.",
    "drug": [
        {
            "name": "Rexulti",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134716"
        }
    ]
}